Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN965724 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Jun Proto-Oncogene (JUN) antibody
- Antibody type
- Polyclonal
- Antigen
- The antiserum was produced against synthesized non-phosphopeptide derived from human c-Jun around the phosphorylation site of serine 63 (L-T-SP-P-D).
- Description
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Vial size
- 100 μg
- Concentration
- 100ug/100ul.
- Storage
- -20°C
Submitted references The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.
c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK).
JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells.
Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus.
Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG Jr
Cancer cell 2005 Jul;8(1):25-33
Cancer cell 2005 Jul;8(1):25-33
c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK).
Sevilla A, Santos CR, Barcia R, Vega FM, Lazo PA
Oncogene 2004 Nov 25;23(55):8950-8
Oncogene 2004 Nov 25;23(55):8950-8
JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells.
Li L, Feng Z, Porter AG
The Journal of biological chemistry 2004 Feb 6;279(6):4058-65
The Journal of biological chemistry 2004 Feb 6;279(6):4058-65
Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus.
Hurd C, Waldron RT, Rozengurt E
Oncogene 2002 Mar 28;21(14):2154-60
Oncogene 2002 Mar 28;21(14):2154-60
No comments: Submit comment
No validations: Submit validation data